title: Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer.
abstract: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation.
  
  
  
  Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastases-free survival and overall survival. In addition to the entire cohort, five tumor- or treatment-related factors were investigated: tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy.
  
  
  
  Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastases-free survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014).
  
  
  
  Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.
authors.affiliation: Departments of Radiation Oncology, University of Lübeck, Lübeck, Germany.
authors.forename: Louisa
authors.initials: L
authors.lastname: Bolm
authors.affiliation: Departments of Radiation Oncology, University of Lübeck, Lübeck, Germany.
authors.forename: Lukas
authors.initials: L
authors.lastname: Kaesmann
authors.affiliation: Hematoogy & Medical Oncology, University of Lübeck, Lübeck, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Bartscht
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Schild
authors.affiliation: Departments of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
authors.forename: Dirk
authors.initials: D
authors.lastname: Rades
mesh_terms: D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
keywords: Non-metastatic bile duct cancer; concurrent radiochemotherapy; local control; metastases-free survival; overall survival; radiotherapy